| RNAZ Stock | | | USD 0.34 0.04 9.71% |
Transcode Therapeutics financial indicator trend analysis is much more than just breaking down Transcode Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Transcode Therapeutics is a good investment. Please check the relationship between Transcode Therapeutics Accounts Payable and its Other Liab accounts. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
For more information on how to buy Transcode Stock please use our
How to Invest in Transcode Therapeutics guide.
Accounts Payable vs Other Liab
Accounts Payable vs Other Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Transcode Therapeutics Accounts Payable account and
Other Liab. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Transcode Therapeutics' Accounts Payable and Other Liab is 0.81. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Liab in the same time period over historical financial statements of Transcode Therapeutics, assuming nothing else is changed. The correlation between historical values of Transcode Therapeutics' Accounts Payable and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Transcode Therapeutics are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Accounts Payable i.e., Transcode Therapeutics' Accounts Payable and Other Liab go up and down completely randomly.
Correlation Coefficient | 0.81 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Accounts Payable
An accounting item on the balance sheet that represents Transcode Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Transcode Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Other Liab
Most indicators from Transcode Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Transcode Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
For more information on how to buy Transcode Stock please use our
How to Invest in Transcode Therapeutics guide.At this time, Transcode Therapeutics'
Selling General Administrative is fairly stable compared to the past year.
Enterprise Value Over EBITDA is likely to rise to 0.07 in 2024, whereas
Issuance Of Capital Stock is likely to drop slightly above 11.7
M in 2024.
Transcode Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Transcode Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Transcode Therapeutics fundamental ratios Accounts
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to
measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.